Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4164332 | 0.90 | AKR1A1 (0.58) | AKR1A1AKR1B1 | |
| SCHEMBL4171191 | 0.89 | AKR1A1 (0.74) | AKR1A1AKR1B1 | |
| SCHEMBL4174302 | 0.83 | AKR1A1 (0.75) | AKR1A1AKR1B1 | |
| SCHEMBL443930 | 0.82 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| SCHEMBL443358 | 0.81 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| Lidorestat SCHEMBL419032 | 0.80 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| Lidorestat SCHEMBL29387869 | 0.80 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| SCHEMBL420815 | 0.80 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| SCHEMBL445827 | 0.80 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| SCHEMBL7511047 | 0.80 | AKR1A1 (0.86) | AKR1A1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444228-B1 | SUBSTITUTED HETEROARYLALKANOIC ACIDS AND THEIR USE AS ALDOSE REDUCTASE INHIBITORS | INST FOR PHARM DISCOVERY INC (US) | 2008-05-21 | — | — | EP | claimed |
| US-20030166668-A1 | Substituted heteroarylalkanoic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, INC. A CORPORATION OF THE STATE OF DELAWARE | 2003-09-04 | — | — | US | claimed |
| US-20090163535-A1 | Substituted Heteroarylalkanoic Acids | THE INSTITUES FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163535-A1 | Substituted Heteroarylalkanoic Acids | THE INSTITUES FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| EP-1444228-B1 | SUBSTITUTED HETEROARYLALKANOIC ACIDS AND THEIR USE AS ALDOSE REDUCTASE INHIBITORS | INST FOR PHARM DISCOVERY INC (US) | 2008-05-21 | — | — | EP | disclosed |
| EP-1444228-B1 | SUBSTITUTED HETEROARYLALKANOIC ACIDS AND THEIR USE AS ALDOSE REDUCTASE INHIBITORS | INST FOR PHARM DISCOVERY INC (US) | 2008-05-21 | — | — | EP | disclosed |
| US-7361671-B2 | Substituted heteroarylalkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361671-B2 | Substituted heteroarylalkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361671-B2 | Substituted heteroarylalkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20030166668-A1 | Substituted heteroarylalkanoic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, INC. A CORPORATION OF THE STATE OF DELAWARE | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163535-A1 | Substituted Heteroarylalkanoic Acids | GPR119, LIPA, LIPC | AKR1A1 138/4885AKR1B1 165/4885 |
| US-20030166668-A1 | Substituted heteroarylalkanoic acids | GPR119, LIPA, DDC | AKR1A1 97/4885AKR1B1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.